Upadacitinib en monothérapie et en association avec des antirhumatismaux modificateurs de la maladie non biologiques dans le traitement du rhumatisme psoriasique
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab905
In this investigation, upadacitinib showed comparable efficacy as monotherapy and in combination with nbDMARDs in PsA. In coming to this conclusion investigators aimed to assess the efficacy and safety of upadacitinib as monotherapy or in combination with nbDMARDs in patients with PsA.